|[January 07, 2014]
ERYTECH Positions Its Lead Product in Solid Tumors and Launches a Phase II Clinical Study in Pancreatic Cancer
LYON, France --(Business Wire)--
ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French
biopharmaceutical company that develops innovative treatments for acute
leukemia and other oncology indications with unmet medical needs,
provides an update on its development plans to broaden the scope of its
lead product ERYASP into the large field of solid tumors and announces
the launch of a Phase II study in pancreatic cancer.
After having performed multiple clinical studies with promising results
in acute leukemia, the research and development teams of ERYTECH have,
in collaboration with researchers at the world renowned MD Anderson
Cancer Center in Houston, worked intensively at confirming the mode of
action and the potential of ERYASP in other cancer indications. In
extensive testing on a large number of tumor samples, it was found and
published in a high ranking peer reviewed journal2 that 50%
to 90% of known solid tumors are eligible for treatment through the
concept of tumor starvation by administration of asparaginase. ERYTECH
has demonstrated that solid tumors such as pancreatic, liver, bladder
and ovarian cancer are potentially sensitive to an asparaginase-based
treatment, which represents a multi-billion market opportunity3
for the product, potentially an order of magnitude much larger than the
already sizeable opportunity in acute leukemia.
The company has retained pancreatic cancer, a very aggressive form of
cancer with few treatment options, as the lead indication for ERYASP in
solid tumors. In Europe and the USA alone, every year about 140,000
patients are newly diagnosed with pancreas cancer. With an overall 5
year survival of 6 to 10%, pancreas cancer is one of the most aggressive
forms of cancer.
Having already successfully completed a Phase I study in late stage
pancreas cancer, in which the tolerability of ERYASP has been confirmed
in this very fragile patient population, ERYTECH has decided to continue
the development in solid tumors by performing a Phase II study in second
line pancreas cancer. In a study of about 100 patients, ERYASP in
addition to the best standard of care will be compared to the best
standard of care alone in a 2-to 1 randomization.
Thanks to an exclusive license from the National Institutes of Health
(NIH) in the USA, ERYTECH has a proprietary companion test allowing to
identify the potential responders to treatment with asparaginase, in
view of offering personalized treatment.
Scientific advice has been obtained from the European Medicines Agency
(EMA (News - Alert)) and a clinical trial application (CTA) has subsequently been
submitted to the ANSM, the French authority for drug safety. Professor
Pascal Hammel, gastro-enterologist and oncologist at Hôpital Beaujon
(Clichy-Paris, France), will be the principal investigator of the study.
Patient enrollment is expected to start in Q2 2014. ERYASP already holds
orphan drug designation for the treatment of pancreas cancer in Europe
and the USA.
"The extensive research work performed by our teams in collaboration
with leading scientists at the MD Anderson Cancer center confirms the
interest of asparaginase based products in the treatment of slid
tumors. Our unique formulation in red blood cells opens the perspective
to offer a therapeutic alternative to a large number of these cancer
patients." said Dr Yann Godfrin, CSO at ERYTECH.
"We look forward to evaluating the efficacy of the ERYASP product in
patients affected by non-resectable pancreas cancer. Asparagine tumor
starvation is an interesting approach to treat cancer and can contribute
to enlarge our therapeutic arsenal against this terrible disease. In
addition the Phase I clinical data showed a good safety profile so far." said
Professor Pascal Hammel, gastro-enterologist and oncologist at Hôpital
About pancreas cancer:
Pancreatic cancer is a disease in which malignant (cancer) cells are
found in the tissues of the pancreas. Every year about 45,000 patients
are diagnosed with pancreatic cancer in the US, and about 95,000 in
Europe. According to the American Cancer Society, for all stages of
pancreatic cancer combined, the one-year relative survival rate is 20%,
and the five-year rate is 6% to 10%. Pancreatic cancer is currently the
fourth most common cause of cancer death in the EU for men and women.
Death rates from the disease are predicted to rise from 7.85 in 2009 to
8.01 in 2013 per 100,000 among men, and from 5.33 to 5.54 per 100,000
among women in same period. In fact, the pancreas is the only major
cancer site for which no improvements in mortality rates is predicated4.
About ERYTECH and ERYASP/GRASPA®: www.erytech.com
Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company
providing new prospects for cancer patients, particularly those with
acute leukemia and selected solid tumors.
Every year about 50,000 patients are diagnosed with Acute Lymphoblastic
Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute
leukemia. Today, for about 80% of these patients, mainly adults and
relapsing patients, there is no adequate solution due to the toxicity of
existing treatments. By encapsulating the asparaginase enzyme in red
blood cells, ERYTECH has developed ERYASP/GRASPA®, an original and
effective treatment that targets leukemia cells through "starvation"
while significantly reducing the side effects for patients, and allowing
all patients to be treated, even the most fragile ones, representing a
market opportunity of more than EUR 1 billion. ERYASP/GRASPA® is
currently completing Phase III clinical development in Acute
Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute
Myeloid Leukemia (AML). The product also received FDA clearance to start
clinical development in ALL in the USA. ERYTECH has concluded
distribution partnership agreements for Europe with Orphan Europe
(Recordati Group), and with TEVA for Israel.
The company is also developing other indications in solid tumors and
certain orphan indications outside oncology. ERYTECH has its own
GMP-approved and operational manufacturing site.
ERYTECH is listed on Euronext regulated market in Paris. (ISIN code:
FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC
Pharm. & Bio and Next Biotech indexes.
This document may contain forward-looking statements and estimates with
respect to the financial situation, the results of operations, the
strategy, the project and to the anticipated future performance of
ERYTECH and of the market in which it operates. Certain of these
statements, forecasts and estimates can be recognized by the use of
words such as, without limitation, "believes", "anticipates", "expects",
"intends", "plans", "seeks", "estimates", "may", "will" and "continue"
and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on
various assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable when made
but may or may not prove to be correct. Actual events are difficult to
predict and may depend upon factors that are beyond the Company's
control. Therefore, actual results, the financial condition, performance
or achievements of ERYTECH, or industry results, may turn out to be
materially different from any future results, performance or
achievements expressed or implied by such statements, forecasts and
estimates. Documents filed by ERYTECH Pharma with the French Autorité
des Marchés Financiers (www.amf-france.org),
also available on our website (www.erytech.com)
describe such risks and uncertainties. Given these uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as of the
date of the publication of this document. ERYTECH disclaims any
obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in the Company's expectations with
regard thereto, or any change in events, conditions or circumstances on
which any such statement, forecast or estimate is based, except to the
extent required by French law.
1 ERYASP is the codename for ERYTECH's lead product,
"Asparaginase encapsulated in red blood cells". The product is named
GRASPA® for indication in acute leukemia in Europe
2 Dufour E et al., Pancreas, 2013
3 Company data
4 Malvezzi M et al., Annals of Oncology 2013, 1-9
[ Back To TMCnet.com's Homepage ]